Acadia Healthcare's (ACHC) third-quarter earnings reflect better performance in its U.S. operations in spite off catastrophe losses playing spoilsport.
Quest Diagnostics (DGX) completes acquisition of outreach laboratory services of two Hartford HealthCare hospitals. The deal is expected to widen the network of the company.
Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.
After the completion of Shiel's acquisition, the medical lab is expected to expand Quest Diagnostics' (DGX) physician and patient service centers network in the New York-New Jersey area.
Американские фондовые индексы завершили снижением торги в понедельник из-за падения акций высокотехнологичных компаний и нового всплеска напряженности в отношениях между США и Северной Кореей.
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
Myriad (MYGN) presenting positive riskScore data at the NSGC conference in Columbus, OH buoys optimism. Notably, with riskScore the company intends to boost its myRisk Hereditary Cancer test suite.
Acadia Healthcare's (ACHC) second-quarter results were boosted by significant revenue growth.
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business in Q2.
Edwards Lifesciences (EW) rides high on continued growth in its highly advanced Transcatheter Heart Valve space in Q2.
Thermo Fisher Scientific (TMO) continues to gain considerable synergies from FEI Company acquisition. A raised guidance buoys optimism.
Anthem's (ANTM) strong second-quarter results were mainly driven by significant rise in medical enrollment, which aided revenue growth.
Universal Health's (UHS) lagged second-quarter earnings primarily due to lower revenues and higher expenses.
Quest Diagnostics (DGX) continues to ride high on its advanced diagnostic offerings. Also, a raised view buoys optimism.
Quest Diagnostics (DGX) gains in Q2 banking on the acquisition of Med Fusion and ClearPoint.
The healthcare sector continues to benefit from higher enrollments, mergers and acquisitions, partly offset by high expense on account of acquisition integration and investments in technology.
Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.
Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.